Monthly subcutaneous migaldendranib shows favorable safety with sustained efficacy through 24 weeks in patients with DME and wet-AMD
Novel subcutaneous delivery may offer a more patient-friendly…Read More
You might also be interested in reading Uniswap v4 taps Celo’s low fees to bring DeFi to the masses.